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Summary
A better understanding about the mechanisms involved in the pathogenesis
of type 2 diabetes mellitus (T2D) showed that inflammatory cytokines such
as tumour necrosis factor (TNF) and interleukin (IL)-1b play a pivotal role,
mirroring data largely reported in rheumatoid arthritis (RA). IL-1b is
produced mainly by monocytes (MO), and hyperglycaemia may be able to
modulate, in the cytoplasm of these cells, the assembly of a nucleotide-
binding domain and leucine-rich repeat containing family pyrin (NLRP3)-
inflammosome, a cytosolic multi-protein platform where the inactive
pro-IL-1b is cleaved into active form, via caspase-1 activity. In this paper, we
evaluated the production of IL-1 b and TNF, in peripheral blood MO of
patients affected by RA or T2D or both diseases, in order to understand if an
alteration of the glucose metabolism may influence their proinflammatory
status. Our data showed, after 24 h of incubation with different glucose
concentrations, a significantly increased production of IL-1b and TNF in all
evaluated groups when compared with healthy controls. However, a
significant increase of IL-1b secretion by T2D/RA was observed when
compared with other groups. The analysis of relative mRNA expression
confirmed these data. After 24 h of incubation with different concentrations
of glucose, our results showed a significant increase in NLRP3 expression. In
this work, an increased production of IL-1b by MO obtained from patients
affected by both RA and T2D via NLRP3-inflammasome activation may
suggest a potential IL-1b targeted therapy in these patients.
Keywords: IL-1b, NLRP3-inflammasome, rheumatoid arthritis, type 2 dia-
betes mellitus
Introduction
Rheumatoid arthritis (RA) is a chronic and disabling dis-
ease characterized by persistent synovitis and systemic
inflammation, in which over-expression of tumour necro-
sis factor (TNF) and interleukin (IL)-1b drive both syno-
vial inflammation and joint destruction [1]. It is well
known that RA is associated with an increased mortality
rate due to the increased risk of cardiovascular (CV) events
when compared with the general population [2–5], and
related to the chronic inflammatory process, which is able
to modulate an accelerated atherosclerosis and CV disease
(CVD) [6]. Both atherosclerosis and RA share common
inflammatory pathways, mediated mainly by TNF and IL-
1b [7–9]. In fact, increased levels of TNF and IL-1b may
promote endothelial dysfunction, structural vessel abnor-
malities, oxidative stress and changes in lipid levels, thus
favouring the appearance of traditional CV risk factors
such as hypertension, insulin resistance and type 2 diabetes
(T2D) [2,10,11]. It is well known that patients affected by
T2D show a higher CV morbidity and mortality when
compared with non-diabetic subjects [12]. In addition, the
diabetic vascular alterations may be responsible for both
diffuse coronary artery disease and stroke, which are
increased significantly in T2D patients, and the risk for the
occurrence of a CV event in these patients, without a pre-
vious history of CVD, mirrors the CV risk observed in
patients with a history of previous myocardial infarction
[13,14]. On this basis, we understand why patients affected
by both RA and T2D displayed the highest risk for CVD
and related mortality [15,16], as suggested by a prospective
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cohort study, conducted in the setting of the CORRONA
registry (Comparative Effectiveness of Biologic and Oral
Agents for the Treatment of Rheumatoid Arthritis), aimed
at investigating the association between CVD and RA
showing that both T2D and RA may contribute to increas-
ing the severity of CVD and in predicting the risk of fatal
CV events [17]. At present, a growing body of evidence
shows the positive association between RA and T2D: dif-
ferent databases, from clinical studies and from national
registers, confirmed that RA patients displayed a double
risk of developing T2D when compared with the general
population [18–20], and epidemiological data strongly
support the association between RA and insulin resistance
[21,22].
In recent years, many papers have supported the role of
inflammatory mechanisms in the pathogenesis of T2D [23]
and recently, as already described for type 1 diabetes melli-
tus (T1D), the pathogenetic role of insulitis in T2D has
been proposed [23–26]. Although the precise aetiology of
the insulitis in both types of diabetes remains to be under-
stood fully, some specific differences have been described.
At present we know that the T1D insulitis is driven by an
autoimmune process, whereas in T2D it is linked to an
autoinflammatory process, involving the IL-1b pathway
[23,24].
Although different cell types may produce IL-1b, this
cytokine is produced mainly by monocytes which, as
shown by preclinical and clinical studies, may be involved
in the pathogenesis of both these diseases [27,28]. Different
pathological stimuli are able to modulate the assembly of a
cytosolic platform, the inflammasome, composed of at least
five different protein components integral to this complex,
including nucleotide-binding domain and leucine-rich
repeat containing family pyrin 3(NLRP3), caspase recruit-
ment domain containing protein 8 (CARD8), pyrin,
apoptosis-associated speck-like protein containing CARD
(ASC) and pro-caspase-1, which is involved mainly in host
defence against microbes and where the inactive pro-IL-1b
is cleaved into a small, mature, active form [29,30].
NLRP3-inflammasome is also activated by host-derived
metabolites, such as monosodium urate crystals, choles-
terol crystals and free fatty acids, and involved in the devel-
opment of some inflammatory diseases such as gout,
atherosclerosis and T2D [23–30].
Of interest, it must be pointed out that recently, in RA
patients, a significantly higher gene expression of ASC,
NLRP3 and CASP1, associated with an increase of caspase-
1 and IL-18 levels, was observed, suggesting that this up-
regulation of NLRP3-inflammasome-related transcripts
may reflect an increased inflammasome activity [31], and
supports the hypothesis that autoinflammatory pathways
may play a pathogenetic role in both diseases.
In this study, we evaluated the production of IL-1b,
TNF, and NLRP3 expression in peripheral blood mono-
cytes (MO) of patients affected by both RA and T2D, after
exposure to different glucose concentrations, to assess the




Between January 2010 and December 2014 we enrolled 10
RA patients, 10 T2D patients and 10 patients affected by
both diseases (T2D/RA patients), according to standard
criteria [32,33], and five healthy controls (HC). Demo-
graphic and clinical features were summarized in Table 1.
T2D patients were eligible if the disease duration was more
than 3 months but less than 1 year, the glycated haemoglo-
bin value between >70 and< 90% at screening time and
no changes in diabetes medications within the last 3
months. RA patients were eligible if their disease duration
was diagnosed from more than 3 months and receiving
only symptomatic therapy [non-steroidal anti-
inflammatory drugs (NSAIDs)]. At the time of enrolment
no patient showed signs and/or symptoms of early
atherosclerosis or CVD, as assessed by flow-mediated dila-
tion of the brachial artery and by intimamedia thickness,
transthoracic Doppler and tissue Doppler echocardiogra-
phy, aortic root echocardiography and pulse-wave velocity
and colour Doppler ultrasounds of the neck vessels. Fur-
thermore, no patient showed clinical and laboratory
parameters compatible with the diagnoses of metabolic
syndrome, essential hypertension, hypercholesterolaemia
or hypertriglyceridaemia. Finally, no patient had smoking
and alcohol habits.
An independent ethics committee approved the study
and all subjects provided written informed consent before
participation; the protocol was according to the Declara-
tion of Helsinki.
Monocyte preparations
Human peripheral blood mononuclear cells (PBMCs) were
isolated from heparinized blood using Ficoll-Hypaque gra-
dients (Histopaque-1077; Sigma, St Louis, MO, USA). MO
were isolated from PBMCs either by positive selection using
magnetic CD14 MicroBeads (human; Miltenyi Biotech,
Bergisch Gladbach, Germany), according to the manufac-
turer’s instructions. Following isolation, MO from our
patients and controls were washed three times in phosphate-
buffered saline, suspended in RPMI-1640 medium (GIBCO/
BRL, Grand Island, NY, USA) containing 10% heat-
inactivated autoserum, 1 3 105 IU/1 penicillin (GIBCO/BRL),
100 mg/1 streptomycin (GIBCO/BRL) and 1000 p-mol/
1 L-glutamine (GIBCO/BRL) and seeded into autoserum-
coated culture plates (Nunclon; Nunc, Roskilde, Denmark).
Aliquots of 13 106 MO were suspended in 1 ml of complete
medium seeded into 24-well culture dishes (Falcon 3047;
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Becton Dickinson, Parsippany, NJ, USA) and incubated with
11 mmol/1 glucose (11G) and 33 mmol/1 glucose (33G) for
24 h in a humidified 5% CO2 incubator at 378C. The choice
of 11G was suggested by the observation that, in humans,
glucose is degraded continuously and formed in order to
maintain a stable concentration of 5 mmol/1 in the blood-
stream. However, in our cell cultures, where glucose is
metabolized but not replaced, cells incubated with a concen-
tration of 5 mmol/1 glucose for 24 h metabolized this mole-
cule strongly, lowering the concentration to less than
2 mmol/1. For this reason, we chose a concentration of 11G,
as in our experience a glucose concentration of 11G does
not lead to glucose deficiency after 24 h of incubation. In
high glucose studies, cells were exposed to a high glucose
concentration of 33G. Many previous studies have reported
that glucose concentrations as high as 50 mmol/1 have been
found in the blood of patients with uncontrolled diabetes
[34,35]. It is true that blood glucose levels in patients are not
likely to remain as high as 33G for 24 h. However, tissue
damage in diabetic patients occurs over many years of
countless hyperglycaemic episodes. Thus, the glucose con-
centration of 33G used in this cell culture study does not
seem unreasonable, as observed in previous work [35].
Lipopolysaccharide (2 ng/ml) was used to stimulate the
secretion of cytokines in cell culture. Media were collected
and stored after 24 h of incubation for the IL-1b and TNF
using a specific enzyme-linked immunosorbent assay
(ELISA).
Measurement of IL-1b and TNF levels by ELISA
The amounts of IL-1b and TNF released in the superna-
tants were determined by using specific Quantikine Human
Immunoassay ELISA kits (all by R&D Systems, Minneapo-
lis, MN, USA), according to the manufacturer’s protocol.
Our results were expressed as median (range). For circulat-
ing levels of IL-1b and TNF, sera were collected from
patients and HC and tested by the same ELISA assays used
for MO culture.
qRT–PCR analysis
RNA were extracted from collected MO using Trizol
(Sigma, St Louis, MO, USA) and reverse-transcribed into
complementary DNA (cDNA) with the ThermoScript
reverse transcription–PCR system (Invitrogen, Carlsbad,
CA, USA). Results were analysed after 40 cycles of
amplification using the ABI 7500 Fast Real Time PCR
System. IL-1b, TNF and NLRP3 gene expression were
assessed by commercial TaqMan gene expression assay
(Hs01555410_m1, Hs01113624_g1 and Hs00918082_m1,
respectively). All gene expression data were normalized to
those for glyceraldehyde 3-phosphate dehydrogenase
(GAPDH).
Western blot
Human MO were washed three times with cold Ca21-free
and Mg-free phosphate-buffered saline (PBS) and lysed by
NP-40 lysis buffer (Boston Biosciences, Ashland, MA,
USA) containing 150 mM phenylmethanesulphonylfluoride
(PMSF) (Fluka Biochemika-Sigma Aldrich, St Louis, MO,
USA) and 1% protease inhibitor cocktail [dissolved in
dimethylsulphoxide (DMSO), Sigma Aldrich]. Lysates were
centrifuged and protein concentrations in supernatants
were determined using the bicinchoninic acid (BCA) assay
(Pierce, Rockford, IL, USA). Equal amounts of protein
were added to the sodium dodecyl sulphide (SDS) sample
buffer containing 2-mercaptoethanol (without boiling),
and electrophoresed on SDS–polyacrylamide gels.
Gels were blotted on nitrocellulose membrane (Invitro-
gen). Blots were blocked overnight in TTBS (TBS-buffer
containing 5% milk powder and 0.05% Tween-20). Blots
were incubated with primary antibodies [room tempera-
ture (RT), 1 h, TTBS], washed three times with TTBS and
then probed with secondary horseradish peroxidase
(HRP)-linked antibodies (RT, 1 h, TTBS; GE Healthcare,
Piscataway, NJ, USA). After repeated washes, blots were
developed by chemiluminescence using the Lumigen DS
detection kit (GE Healthcare). The primary antibodies
used were: NLRP3 (R&D Systems). All the signals were
Table 1. Demographic and clinical features.
HC T2D RA T2D/RA
Patients 5 10 10 10
Female (male) 3 (2) 5 (5) 6 (4) 6 (4)
Age (years), median (range) 48 (40; 50) 46 (40; 62) 44 (39; 58) 45 (41; 58)
Disease duration (years), median (range) 06 (05; 1) 51 (12; 63) T2D 06 (05; 1)
RA 52 (27; 72)
Fasting blood glucose (mg/dl) 80 (70; 90) 126 (100; 164) 90 (70; 105) 129 (105; 156)
Glycated haemoglobin (%) 52 (48; 53) 74 (71; 78) 54 (49; 58) 75 ( 72; 78)
Erythrocytes sedimentation rate (mm/h) 4 (0; 8) 8 (4; 12) 18 (10; 25) 16 (8; 30)
C reactive protein (mg/l) 12 (01; 34) 44 (18; 62) 42 (28; 52) 44 (18; 62)
Metformin (dosage, mg/daily) median (range) None 1500 (1000; 2000) None 1500 (1000; 2000)
HC5 healthy control; T2D5 type 2 diabetes mellitus; RA5 rheumatoid arthritis.
T2D/RA monocytes and IL-1b production
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quantified by normalizing to the tubulin signal (Abcam,
Cambridge, MA, USA). Immunoreactive bands were quan-
tified with densitometry using ImageJ software (NIH,
Bethesda, MD, USA).
Statistical analysis
GraphPad Prism version 50 software was used for statisti-
cal analyses. Results are expressed as median (range). Due
to the non-parametric distribution of our data the Mann–
Whitney U-test was used as appropriate for analyses.
Despite the small numbers of patients enrolled into each
studied group, the strong a priori evidence of an increased
NLPR3 activation associated with both RA and T2D
[24,29,31] allowed us to not apply Bonferroni’s correction
in our statistical analyses. Statistical significance was
expressed by a P-value< 005.
Results
Increased secretion of IL-1b after high concentration
glucose stimulation in supernatants of cultured cells
Our data showed that, after 24 h of incubation with 11G, a
significant increase of IL-1b levels was shown when T2D,
RA and T2D/RA patients were compared with HC [HC:
45 (41; 58) pg/ml; T2D: 480 (201; 636) pg/ml; RA: 550
(345; 1052); T2D/RA: 545 (325; 1024) pg/ml; P < 001
for each comparison]. Furthermore, no significant differen-
ces in IL-1b levels were observed among patient groups.
On the contrary, after 24 h of incubation with 33G a signif-
icant increase in IL-1b levels were observed in the superna-
tants of T2D/RA patients when compared with HC and
among other evaluated groups [HC: 1353 (1081; 2568)
pg/ml; T2D: 2082 (1231; 3006) pg/ml; RA: 2010
(1685; 2082) pg/ml; T2D/RA 3525 (2575; 7119) pg/ml;
P < 0.01 for each comparison]. No significant differences
were observed when we compared RA patients and T2D
patients with HC.
Our results showed that, after 24 h of incubation with
11G, a significant increase in TNF levels was shown when
T2D, RA and T2D/RA patients were compared with HC
[HC: 214 (202; 236) pg/ml; T2D: 3561 (2341; 6953)
pg/ml; RA: 4375 (3565; 9702) pg/ml; T2D/RA: 4962
(4267; 7705) pg/ml in T2D/RA patients; P < 0.01 for each
comparison].No significant differences in TNF levels were
observed among patient groups. Our data showed that,
after 24 h of incubation with 33G, a significant increase in
TNF levels was shown when T2D, RA and T2D/RA patients
were compared with HC [HC: 1354 (1082; 2563) pg/ml;
T2D: 7335 (5002; 10081) pg/ml; RA: 7785 (5701;
10070) pg/ml; T2D/RA: 8004 (4371; 11306) pg/ml; P <
0.01 for each comparison]. No significant differences in
TNF levels were observed among patient groups. These
results are summarized in Fig. 1.
Increased expression of IL-1b after high
concentration glucose stimulation
Our data showed that, after 24 h of incubation with 11G, a
significant increase in relative IL-1b mRNA expression was
reported when T2D, RA, and T2D/RA patients were com-
pared with HC [HC: 15 (10; 20); T2D: 52 (45; 69); RA:
48 (32; 62); T2D/RA 57 (45; 69) patients; P < 001 for
each comparison]. No significant differences in relative IL-
1b mRNA expression were observed among patient groups.
However, after 24 h of incubation with 33G a significant
increase in relative IL-1b mRNA expression was observed
in the supernatants of T2D/RA patients when compared
with HC and among other evaluated groups [HC: 32 (20;
57); T2D: 145 (120; 180); RA: 158 (142; 194); T2D/
RA: 243 (200; 272); P < 0001 for each comparison]. Sig-
nificant differences were observed when we compared both
RA patients and T2D patients with HC (P < 0.01 for each
comparison).
Our results showed that, after 24 h of incubation with
11G, a significant increase of relative TNF mRNA expres-
sion was shown when T2D, RA and T2D/RA patients were
compared with HC [HC: 12 (10; 22); T2D: 57 (45; 68);
RA: 62 (48; 90); T2D/RA: 58 (45; 76); P < 0001 for
each comparison]. Our work showed that, after 24 h of
incubation with 33G, a significant increase of relative TNF
mRNA expression was shown when T2D, RA and T2D/RA
patients were compared with HC [HC: 62 (60; 72); T2D:
147 (141; 182);RA: 158 (140; 180); T2D/RA: 155 (148;
186); P < 001 for each comparison]. No significant differ-
ences in TNF levels were observed among patient groups.
All these data are reported in Fig. 2.
Increased expression of NLRP3-inflammosome
in T2D/RA patients
After 24 h of incubation to 11G our results showed a signif-
icant increase in relative NLRP3 mRNA expression of T2D/
RA patients when compared with other groups [HC: 12
(10; 20); T2D: 51 (45; 79); RA: 36 (32; 59); T2D/RA:
75 (69; 109); P < 0001 for each comparison]. In addi-
tion, we reported a significantly higher relative NLRP3
mRNA expression when compared T2D and RA patients
with HC (P < 001 for each comparison). A significantly
higher relative NLRP3 mRNA expression in T2D patients
with respect to RA patients was shown (P < 001) at the
same glucose concentration. After 24 h of incubation with
33G our results showed a significant increase in relative
NLRP3 mRNA expression when we compared T2D/RA
patients to other groups [HC: 42 (20; 50); T2D: 164
(154; 188); RA: 138 (100; 180); T2D/RA: 228 (209;
270); P < 0001 for each comparison]. We described a sig-
nificantly higher relative NLRP3 mRNA expression when
we compared T2D and RA patients with HC (P < 001 for
each comparison). A significantly higher relative NLRP3
mRNA expression in T2D patients in respect to RA patients
P. Ruscitti et al.
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was shown (P < 001) at the same glucose concentration.
These data were confirmed by Western blot analyses. This
analysis mirrored the results obtained by evaluation of
NLRP3 mRNA expression; Fig. 3 shows these findings.
No differences in circulating levels of IL-1b and TNF
were observed
When we analysed the circulating levels of IL-1b among
enrolled patients we did not find significant differences
[HC: 15 (11; 18) pg/ml; T2D: 11 (12; 18) pg/ml; RA:
59 (15; 28) pg/ml; T2D/RA: 1,9 (15;23) pg/ml]. Simi-
larly, the analysis of the circulating levels of TNF among
enrolled patients did not show significant differences [HC:
29 (02; 36) pg/ml; T2D: 28 (12; 39) pg/ml; RA: 27
(05; 41) pg/ml; T2D/RA: 31 (04; 46) pg/ml].
Discussion
In recent years, the involvement of innate immunity has
been suggested in the pathogenesis of T2D [23–30], and
several studies have described elevated circulating levels of
acute-phase proteins, cytokines and chemokines in patients
with T2D, and elevated levels of IL-1b, IL-6 and C-reactive
protein have been suggested as predictive factors of T2D
development [36–39]. In addition, an immune cell infiltra-
tion surrounding the pancreatic islets in human T2D, char-
acterized largely by MO, may be observed [39]. On this
basis, a better knowledge of the metabolically driven
inflammation observed in T2D may open future perspec-
tives, identifying new potential biomarkers and/or new
therapeutic targets [23–30]. In this regard, several papers
have suggested, both in experimental models and in
humans, the usefulness of cytokine antagonism therapies
Fig. 2. Increased relative expression of interleukin (IL)-1b (a) and tumour necrosis factor (TNF) (b) after glucose stimulation in cultured cells.
Monocytes were incubated with 11 mmol/1 glucose (11G) and 33 mmol/1 glucose (33G) for 24 h. Our data showed that, after 24 h of
incubation with 11G, a significant increase of relative IL-1b and TNF mRNA expressions were reported when type 2 diabetes (T2D), rheumatoid
arthritis (RA) and T2D/RA patients were compared with healthy controls (HC) (P < 0001 for each comparison). However, after 24 h of
incubation with 33G a significant increase in relative IL-1b mRNA expression was observed in the supernatants of T2D/RA patients when
compared with HC and among other evaluated groups (P < 001 for each comparison) (***P < 0001).
Fig. 1. Increased secretion of interleukin (IL)-1b (a) and tumour necrosis factor (TNF) (b) after glucose stimulation in supernatants of cultured
cells. Monocytes were incubated with 11 mmol/1 glucose (11G) and 33 mmol/1 glucose (33G) for 24 h. Our data showed that, after 24 h of
incubation with 11G, a significant increase of IL-1b and TNF levels were shown when type 2 diabetes (T2D), rheumatoid arthritis (RA) and
T2D/RA patients were compared with healthy controls (HC) (P < 001 for each comparison). After 24 h of incubation with 33G, a significant
increase in IL-1b levels were observed in the supernatants of T2D/RA patients when compared with all evaluated groups (P < 001 for each
comparison) (**P < 001).
T2D/RA monocytes and IL-1b production
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in T2D, mirroring what has been suggested for RA and
other inflammatory arthritis [23,24].
In this paper, we show that increased concentrations of
glucose strongly influence the proinflammatory status of
MO derived from patients affected by RA and concomitant
T2D, suggesting that the altered glucose metabolism,
increasing the production of inflammatory cytokines, may
affect the clinical picture of RA and influences the response
to targeted therapies [1,2,5,8–10].
After incubation of MO with different glucose concen-
trations, we observed an increased production of IL-1b in
any studied subset correlating directly with glucose concen-
trations, the highest levels observed in patients affected by
both diseases. It is well known that hyperglycaemia levels
may up-regulate the expression of different transcription
factors of many proinflammatory cytokine genes [40–42].
Among them, the transcription factor nuclear factor
(NF)-jB may mediate the increased IL-1b secretion from
MO exposed to hyperglycaemic conditions [43,44]. Analy-
ses of IL-1b mRNA confirmed these results, showing a sig-
nificant increase of its expression in T2D/RA patients when
compared with other groups.
It is well known that, during T2D, the polarity of islet-
infiltrating MO is shifted towards the activated proinflam-
matory M1-type, releasing higher concentrations of IL-1b
[45]. Experimental models of T2D showed that during
euglycaemic conditions MO exhibit a M2-type phenotype,
promoting wound healing and modulating immune
responses. Conversely, under the influence of hyperglycae-
mia, these M2-type MO shift to a M1-type phenotype,
starting the production of inflammatory cytokines such as
IL-1b, and leading to a fibrotic degeneration associated
with amyloid deposits of Langerhans islets [27,45]. In this
setting, the higher levels of IL-1b have been shown to drive
the progressive failure of insulin production and apoptosis
of b cells [46,47]. Furthermore, glucose-induced IL-1b
production by MO involved up-regulation of the NLRP3-
inflammasome [48]. Higher concentrations of glucose may
induce the dissociation of thioredoxin-interacting protein
(TXNIP) from thioredoxin, under the influence of reactive
oxygen species, allowing the binding of TXNIP to the
NLRP3-inflammasome. This event leads to the activation
of caspase-1 and subsequent release of mature IL-1b from
inactive pro-IL-1b [49]. Interestingly, confirming the
results concerning IL-1b production, a significantly higher
expression of NLRP3-inflammasome was observed after
incubation with different glucose concentrations in T2D/
RA patients when compared with the other groups.
Regarding the role of NLRP3-inflammasome in glucose
and insulin homeostasis, several preclinical studies showed
that the genetic deletion of NLRP3 in high-fat diet-fed
mice improved glucose tolerance and enhanced insulin sen-
sitivity [50,51]. These data were confirmed in NLRP32/2
knock-out animals, where the IL-1b levels in the adipose
tissue decreased significantly; this reduction is associated
with lower levels of caspase-1 activity [51]. Furthermore,
inhibition of NLRP3-inflammasome is associated with
improved insulin signalling in adipose tissue, liver and skel-
etal muscles, which are considered insulin-sensitive tissue,
and with increased insulin secretion from b islets [50–53].
Our data also showed increased production of TNF
from MO obtained from T2D/RA, T2D and RA patients
after exposure to different glucose concentrations when
compared to HC, although no significant difference was
observed among the studied subsets. The available litera-
ture reports that the expression of TNF in adipose tissue
was increased in multiple rodent obesity models, and this
cytokine may decrease insulin signalling in insulin-sensitive
tissues [54–56]. Furthermore, in these experimental mod-
els, weight loss may induce an improvement in insulin sen-
sitivity that has been associated with a reduction in TNF
expression [54–57]. According to these experimental
Fig. 3. Increased relative expression of nucleotide-binding domain and leucine-rich repeat containing family pyrin (NLRP3) (a) after glucose
stimulation and Western blot analyses (b). Monocytes were incubated with 11 mmol/1 glucose (G11), 33 mmol/1 glucose (G33). The expression
levels of healthy controls (HC) incubated with 11 mmol/1 glucose (G11) were set to 100%, and the results were normalized to this value.
Tubulin was measured as a loading control for normalization. After 24 h of incubation to 11G our results showed a significant increase in
relative NLRP3 mRNA expression in type 2 diabetes/rheumatoid arthritis (T2D/RA) patients when compared with other groups (P < 0001 for
each comparison). After 24 h of incubation to 33G the results showed a significant increase in relative NLRP3 mRNA expression when we
compared T2D/RA patients to other groups (P < 0001 for each comparison). This analysis mirrored the results obtained by evaluation of
NLRP3 mRNA expression by Western blot (**P < 001; ***P < 0001, respectively).
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findings, studies using TNF2/2 knock-out mice, or alterna-
tively neutralizing TNF activity by specific antibodies,
showed an improvement in glycaemia levels, suggesting
TNF as potential therapeutic target for T2D [54–57].
Despite the experimental evidence supporting a role for
TNF in regulating insulin production and function, the
translation from basic researches to the clinical setting by
using TNF inhibitors in the treatment of human diabetes
showed disappointing results [58–60]. Although further
studies are needed to understand more clearly the failure of
TNF inhibition in human diabetes, it must be pointed out
that the intracellular TNF concentration is responsible for
insulin resistance via paracrine effects, and this intracellular
cytokine cannot be blocked by TNF inhibitors [61].
In contrast, several published studies suggest the possible
therapeutic role of IL-1 antagonism in T2D [62,63]. In this
context, 70 T2D patients, assigned randomly to receive
100 mg of anakinra, an IL-1 receptor antagonist licensed for
RA or placebo, showed a significant decrease in the glycated
haemoglobin level and an increase of C-peptide secretion
after 13 weeks of treatment [64]. The follow-up of these
patients showed that this improvement was still detectable
39 weeks after discontinuation of anakinra [65]. Further-
more, the results of a 1-year prospective observational study
enrolling 470 RA patients treated with anakinra showed that
RA patients with concomitant T2D displayed a better
response to this drug [66]. These data suggest that T2D co-
morbidity in RA patients predicts those patients with a bet-
ter response to IL-1 inhibition. In addition, different papers
suggest that IL-1 blockade may be helpful in patients with
T2D and inflammatory rheumatic diseases [67,68]. On this
basis, an open, randomized, controlled, double-armed,
multi-centre study, whose primary end-point is the efficacy
of anakinra in controlling signs and symptoms of T2D in
RA patients and T2D co-morbidity, is ongoing (TRACK
study, NCT02236481, www.clinicaltrial.gov).
It is well known that both T2D and RA are independent
factors increasing the risk of CV events in affected patients
and these data are related to the chronic inflammatory
activity observed in both diseases, mediated by the over-
production of inflammatory cytokines [16,17,23,24,28]. In
addition, a large body of preclinical data showed that IL-1b
is involved strongly in the progression of atherosclerosis
[69,70]. During the inflammatory process occurring in RA,
it has been shown that TNF may contribute to endothelial
dysfunction [71]. However, conflicting results have been
published concerning the possibility that an anti-TNF ther-
apy might restore normal endothelial function [72,73].
Furthermore, it has been shown recently that the decrease
of inflammatory markers, after anti-TNF treatment, were
not associated with an improvement in vascular function
[74,75]. On the contrary, different works suggest that the
IL-1 inhibition may be associated with a greater improve-
ment of endothelial function in RA patients [76,77]. Heart
failure is a common evolution of atherosclerosis, and sev-
eral studies have shown the safety and the usefulness of
anti-IL-1 treatment in this condition, a clinical setting in
which anti-TNF treatment is contraindicated [78–81]. It is
well known that the incidence of impaired cardiac function
is increased strongly both in RA and T2D, leading to a
poor prognosis [82,83]. In this context, our experimental
data, showing a strong up-regulation of IL-1b MO derived
from patients with both RA and T2D, may support the
hypothesis that blocking IL-1b may be considered the best
therapeutic strategy to treat these patients, due to the up-
regulation of this cytokine in these patients and to the
safety shown during chronic heart failure. On this basis,
the scientific community is still waiting for the results of
the CANTOS (Canakinumab Anti-inflammatory Throm-
bosis Outcome Study) trial, a study planned to test the
hypothesis that the inhibition of IL-1b by Canakinumab, a
human IL-1b blocking monoclonal antibody, might reduce
CV events in T2D [84,85].
IL-1 blocking agents are generally considered safe drugs.
Although the occurrence of upper-airway infections may
increase in patients receiving anti-IL-1 therapy, as observed
with the other biological agents, the lack of opportunistic
and tuberculosis infections confirms their safety profile
[86,87].
In conclusion, although further studies are needed to
understand fully the complex interplay between inflamma-
tion and metabolic disorders and consequent therapeutic
implications, our study, showing an increased production of
IL-1b by MO obtained from patients affected by both RA
and T2D via NLRP3-inflammasome activation, supports the
potential role of IL-1b-targeted therapy in these patients.
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